New hope for women with returning cervical cancer
NCT ID NCT04341883
Summary
This study tested a new treatment combination for women whose cervical cancer has returned after standard chemotherapy. It combined an immunotherapy drug (anti-PD-1) with a chemotherapy drug (albumin-bound paclitaxel) to see if it could shrink tumors and control the disease. The goal was to find a new option for patients who have run out of effective treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.